Delivery Order SPE2DR25D3103-SPE2DR26F9Q87
- Not listed
- The Defense Logistics Agency awarded a $2,287.88 firm fixed-price delivery order to AmerisourceBergen Drug Corp on October 16, 2025, for the supply of Actemra ActPen 162 mg/0.9 mL auto-injector units. The contract, which carries an ultimate completion date of October 17, 2025, represents a non-set-aside competitive award with performance to be executed at the vendor's Conshohocken, Pennsylvania location. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on November 20, 2025, for the supply of Actemra Actpen 162 mg/0.9 ml auto-injector pens, with a ceiling value of $1,259.18. This is a firm fixed-price delivery order with no set-aside designation, indicating competitive award through open procurement. The order is set for ultimate completion by November 21, 2025, and will be fulfilled from the vendor's location in Conshohocken, Pennsylvania. This delivery...
- AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, was awarded a delivery order for Actemra ActPen 162 mg/0.9 mL auto-injectors by the Defense Logistics Agency on December 18, 2025, with an ultimate completion date of December 19, 2025. The contract is structured as a firm fixed-price delivery order with a ceiling value of $4,327.94 and carries no set-aside designation, indicating it was competitively awarded. This delivery order is issued under AmerisourceBergen's...
- The Defense Logistics Agency awarded a $3,616.62 firm fixed-price delivery order to AmerisourceBergen Drug Corp on December 2, 2025, for the supply of Actemra Actpen 162 mg/0.9 mL auto-injector pens. The performance location is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania, with an ultimate completion date of December 3, 2025. This delivery order was competitively awarded without a set-aside designation and represents a child contract under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a Delivery Order to AmerisourceBergen Drug Corp on November 28, 2025, for the supply of Actemra ActPen 162 mg/0.9 ml auto-injectors with a ceiling value of $8,352.14. This is a firm fixed-price order with an ultimate completion date of December 1, 2025, and represents a non-competitive set-aside delivery against AmerisourceBergen's existing indefinite delivery contract (IDC) vehicle. The place of performance is AmerisourceBergen's corporate office location in...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $10,906.05 on September 22, 2025, for the supply of Actemra Actpen 162 mg/0.9 mL auto-injector pens. This competitively awarded, firm fixed-price contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The delivery order will be fulfilled from the contractor's...
- The Defense Logistics Agency awarded a delivery order valued at $1,143.94 to AmerisourceBergen Drug Corp for the supply of Actemra ActPen 162 mg/0.9 mL auto-injector pens. This firm fixed price delivery order was competitively awarded without set-aside designation and is scheduled for completion by September 9, 2025. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its primary operations as a major...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on December 3, 2025, for the supply of Actemra ActPen 162 mg/0.9 mL auto-injector pens with a ceiling value of $1,205.54 and a firm fixed price structure. This delivery order is non-set-aside and represents a competitive award, with an ultimate completion date of December 4, 2025. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on November 3, 2025, for the supply of Actemra Actpen 162 mg/0.9 ml auto-injector pens, with a ceiling value of $1,205.54 and a firm fixed price structure. This is a non-set-aside, competitively awarded delivery order with an ultimate completion date of November 4, 2025, and will be performed at the awardee's corporate office location in Conshohocken, Pennsylvania. As a child contract, this delivery order...
- The Defense Logistics Agency awarded a delivery order valued at $92,517.65 to AmerisourceBergen Drug Corp for the supply of Actemra ActPen 162 mg/0.9 mL auto-injector pens. The contract, executed on November 25, 2025, with an ultimate completion date of November 26, 2025, utilizes firm fixed pricing with no set-aside designation, indicating competitive award. Performance will be executed from the vendor's location in Conshohocken, Pennsylvania. This delivery order is issued under...
- SPE2DR25D3103Indefinite Delivery Contract
- SPE2DR25D3103-SPE2DR26F9Q87Delivery Order
The Defense Logistics Agency awarded a delivery order valued at $2,310.51 to AmerisourceBergen Drug Corp for the supply of Actemra ActPen 162 mg/0.9 mL auto-injector pens. This contract, awarded on December 18, 2025, with an ultimate completion date of December 19, 2025, represents a firm fixed-price delivery order with no set-aside designation. The product will be delivered to the company's corporate office location in Conshohocken, Pennsylvania. As a competitive award, this delivery order demonstrates AmerisourceBergen's continued capability to meet federal pharmaceutical procurement requirements through open competition. This delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a comprehensive pharmaceutical prime vendor agreement valued at $999,999,999.00 and extending through December 2026. This prime contract vehicle enables the company to supply a broad range of pharmaceutical products and medical supplies to support military healthcare systems globally, including the Defense Health Agency and U.S. Coast Guard. Actemra (tocilizumab) is a specialty biologic medication used in the treatment of rheumatoid arthritis and other inflammatory conditions, reflecting the scope of specialty medications included within AmerisourceBergen's federal pharmaceutical supply portfolio.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.3k | 12/17/25 |